Kane Biotech (CVE:KNE) Trading Down 23.1% – What’s Next?

Kane Biotech Inc. (CVE:KNE)’s share price traded down 23.1% during mid-day trading on Friday . The company traded as low as C$0.05 and last traded at C$0.05. 159,625 shares changed hands during mid-day trading, an increase of 120% from the average session volume of 72,560 shares. The stock had previously closed at C$0.07.

Kane Biotech Trading Down 23.1%

The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The business’s 50 day moving average price is C$0.08 and its 200-day moving average price is C$0.10. The firm has a market cap of C$7.20 million, a price-to-earnings ratio of 1.25 and a beta of 0.52.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.